Some disappointing news from my colleague Matthew Swanson in WA state, indicating limited value in currently available medical treatments, including the much-touted Remdesivir.

“You will all read a lot about medication trials for coronavirus in the coming months. I encourage you to read the study, not the headline. Currently there are no medications shown by rigorous evidence to reduce mortality in coronavirus patients. Many medications are harmful, as we have seen in early results from hydroxychloroquine trials. Hence, experimental use of medications should be confined to studies until better evidence is available. NIAID’s Remdesivir trial results announced today do show a clinically significant shortening in recovery time for patients with advanced disease, but no significant mortality benefit in these patients. This information should not change our current use of this medication (limited to clinical trials and case by case compassionate use in the critically ill) and suggests more studies should be done.”